Oramed Pharmaceuticals Stock Performance
| ORMP Stock | USD 3.25 0.13 3.85% |
On a scale of 0 to 100, Oramed Pharmaceuticals holds a performance score of 14. The company holds a Beta of 2.09, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Oramed Pharmaceuticals will likely underperform. Please check Oramed Pharmaceuticals' maximum drawdown, and the relationship between the information ratio and expected short fall , to make a quick decision on whether Oramed Pharmaceuticals' historical price patterns will revert.
Risk-Adjusted Performance
Solid
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Oramed Pharmaceuticals are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. Even with relatively weak primary indicators, Oramed Pharmaceuticals reported solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (3.85) | Five Day Return (0.91) | Year To Date Return 11.68 | Ten Year Return (45.38) | All Time Return (72.92) |
Forward Dividend Yield 0.074 | Payout Ratio | Last Split Factor 1:12 | Forward Dividend Rate 0.25 | Dividend Date 2026-01-26 |
1 | Lifeward Ltd. Reports Third Quarter 2025 Financial Results | 11/14/2025 |
2 | Oramed Pharmaceuticals GAAP EPS of 1.26 | 11/17/2025 |
3 | What market sentiment indicators show for Oramed Pharmaceuticals Inc. stock - Market Risk Report Safe Entry Momentum Stock Tips - newser.com | 11/19/2025 |
4 | ORMP Advancing Clinical Activities, Generating Gains From Investment Portfolio, New Rights Plan Adopted | 11/24/2025 |
5 | Oramed Pharmaceuticals And 2 Other Promising Penny Stocks To Watch | 12/16/2025 |
6 | Acquisition by Kidron Nadav of 109000 shares of Oramed Pharmaceuticals subject to Rule 16b-3 | 12/30/2025 |
7 | Acquisition by Avraham Gabay of 19000 shares of Oramed Pharmaceuticals subject to Rule 16b-3 | 12/31/2025 |
8 | Oramed Receives 18 Million Payment from Scilex Holdings, Bringing Current Returns to 118 Million Board Approves Dividend Payments | 01/07/2026 |
9 | Disposition of 86166 shares by Miriam Kidron of Oramed Pharmaceuticals subject to Rule 16b-3 | 01/14/2026 |
10 | Disposition of 109000 shares by Kidron Nadav of Oramed Pharmaceuticals subject to Rule 16b-3 | 01/22/2026 |
| Oramed Pharmaceuticals dividend paid on 26th of January 2026 | 01/26/2026 |
11 | NNDM Stock In Focus Nano Dimension Pops A Poison Pill Days After Oramed Stake Build-Up - Stocktwits | 02/02/2026 |
| Begin Period Cash Flow | 9.1 M | |
| Total Cashflows From Investing Activities | 105.8 M |
Oramed Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 224.00 in Oramed Pharmaceuticals on November 13, 2025 and sell it today you would earn a total of 101.00 from holding Oramed Pharmaceuticals or generate 45.09% return on investment over 90 days. Oramed Pharmaceuticals is currently generating 0.6756% in daily expected returns and assumes 3.6391% risk (volatility on return distribution) over the 90 days horizon. In different words, 32% of stocks are less volatile than Oramed, and 87% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Oramed Pharmaceuticals Target Price Odds to finish over Current Price
The tendency of Oramed Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 3.25 | 90 days | 3.25 | about 19.92 |
Based on a normal probability distribution, the odds of Oramed Pharmaceuticals to move above the current price in 90 days from now is about 19.92 (This Oramed Pharmaceuticals probability density function shows the probability of Oramed Stock to fall within a particular range of prices over 90 days) .
Oramed Pharmaceuticals Price Density |
| Price |
Predictive Modules for Oramed Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Oramed Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Oramed Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Oramed Pharmaceuticals is not an exception. The market had few large corrections towards the Oramed Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Oramed Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Oramed Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.56 | |
β | Beta against Dow Jones | 2.09 | |
σ | Overall volatility | 0.45 | |
Ir | Information ratio | 0.18 |
Oramed Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Oramed Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Oramed Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Oramed Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (19.06 M) with profit before overhead, payroll, taxes, and interest of 13 K. | |
| Oramed Pharmaceuticals currently holds about 133.91 M in cash with (8.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.45, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Oramed Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Roughly 15.0% of the company outstanding shares are owned by corporate insiders | |
| On 26th of January 2026 Oramed Pharmaceuticals paid $ 0.25 per share dividend to its current shareholders | |
| Latest headline from thelincolnianonline.com: Coya Therapeutics Buy Rating Reiterated at HC Wainwright |
Oramed Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Oramed Stock often depends not only on the future outlook of the current and potential Oramed Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Oramed Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 40.8 M | |
| Cash And Short Term Investments | 141.9 M |
Oramed Pharmaceuticals Fundamentals Growth
Oramed Stock prices reflect investors' perceptions of the future prospects and financial health of Oramed Pharmaceuticals, and Oramed Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Oramed Stock performance.
| Return On Equity | 0.24 | ||||
| Return On Asset | -0.0422 | ||||
| Profit Margin | 21.93 % | ||||
| Operating Margin | (6.51) % | ||||
| Current Valuation | 705.3 K | ||||
| Shares Outstanding | 39.8 M | ||||
| Price To Earning | (11.22) X | ||||
| Price To Book | 0.66 X | ||||
| Price To Sales | 64.75 X | ||||
| Gross Profit | 13 K | ||||
| EBITDA | (14.87 M) | ||||
| Net Income | (19.06 M) | ||||
| Cash And Equivalents | 133.91 M | ||||
| Cash Per Share | 3.45 X | ||||
| Total Debt | 372 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 21.01 X | ||||
| Book Value Per Share | 4.98 X | ||||
| Cash Flow From Operations | (8.41 M) | ||||
| Earnings Per Share | 0.96 X | ||||
| Market Capitalization | 129.51 M | ||||
| Total Asset | 155.28 M | ||||
| Retained Earnings | (176.62 M) | ||||
| Working Capital | 137.54 M | ||||
| Current Asset | 31 M | ||||
| Current Liabilities | 4 M | ||||
About Oramed Pharmaceuticals Performance
Assessing Oramed Pharmaceuticals' fundamental ratios provides investors with valuable insights into Oramed Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Oramed Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.11) | (0.12) | |
| Return On Capital Employed | (0.08) | (0.08) | |
| Return On Assets | (0.11) | (0.12) | |
| Return On Equity | (0.13) | (0.12) |
Things to note about Oramed Pharmaceuticals performance evaluation
Checking the ongoing alerts about Oramed Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Oramed Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Oramed Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (19.06 M) with profit before overhead, payroll, taxes, and interest of 13 K. | |
| Oramed Pharmaceuticals currently holds about 133.91 M in cash with (8.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.45, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Oramed Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Roughly 15.0% of the company outstanding shares are owned by corporate insiders | |
| On 26th of January 2026 Oramed Pharmaceuticals paid $ 0.25 per share dividend to its current shareholders | |
| Latest headline from thelincolnianonline.com: Coya Therapeutics Buy Rating Reiterated at HC Wainwright |
- Analyzing Oramed Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Oramed Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Oramed Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Oramed Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Oramed Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Oramed Pharmaceuticals' stock. These opinions can provide insight into Oramed Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Oramed Stock Analysis
When running Oramed Pharmaceuticals' price analysis, check to measure Oramed Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oramed Pharmaceuticals is operating at the current time. Most of Oramed Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Oramed Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oramed Pharmaceuticals' price. Additionally, you may evaluate how the addition of Oramed Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.